MEMPHASYS ORD
Memphasys Secures CE Mark for Felix System, Unlocking European Market
Memphasys (ASX: MEM) has secured CE Mark approval for its Felix System, unlocking immediate commercial opportunities in Europe and activating binding multi-year contracts in Europe and MENA.
Memphasys Signs Agreement to Distribute Felix Fertility Device Across Middle East and North Africa
Memphasys (ASX: MEM) has granted Qatar-based company International Technical Legacy (ITL) exclusive commercial and distribution rights to its innovative Felix male fertility sperm preparation system. The five-year deal applies to approximately 353 clinics across 15 countries across the Middle East and North Africa, which perform a cumulative 140,000 in vitro fertilisation (IVF) cycles per year. […]
Memphasys pilot study confirms RoXsta’s potential as high-throughput antioxidant diagnostic tool
A pilot study has shown that Memphasys’ (ASX: MEM) RoXsta Mega Cell high-throughput assay device can conduct large-scale, simultaneous antioxidant assays within a lab setting. The study demonstrated that the next-generation analytical platform was able to process 96 samples in less than one hour, returning highly accurate antioxidant readings for individuals requiring antioxidant therapy. The […]
Memphasys achieves key milestone with clinical validation of Felix fertility device
Memphasys (ASX: MEM) has published positive data from a pivotal clinical trial of its Felix electrophoresis-based sperm separation device for use in assisted reproduction. The trial validated the ability of the Felix device to meet and exceed industry benchmarks and found it to be non-inferior to the “swim-up” technique but statistically superior to DGC (density-gradient […]